Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enGene Therapeutics Inc.ENGN · Entity 6638 | Chief Medical Officer | January 29, 2025 | January 31, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enGene Therapeutics Inc.
Report date January 29, 2025 · Filed January 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2035-01-29 | Direct | 280,000 |
Reported balance
After 2025-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-29 · Grant · Acquired 280,000 · Balance 280,000 F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2025 Filed Jan 31, 2025 16:46 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0000929638-25-000481 · form4.xml · derivative · entry 1 Pruthi Raj Som · CIK 0002030291 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 280,000 shares Expires 2035-01-29 F1 · derivative.exercise_date: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. Read SEC document |
| July 24, 2024 Filed Jul 25, 2024 20:32 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0000929638-24-002597 · form4.xml · derivative · entry 1 Pruthi Raj Som · CIK 0002030291 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Shares · 110,000 shares Expires 2034-07-24 F1 · derivative.exercise_date: This option vests at 25% on July 24, 2025, which is the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.